India, Sept. 28 -- The Indian pharmaceuticals industry is witnessing a trend towards complex drugs and biosimilars, as firms try to grow their footprint in the high-end niche market segment. Regulatory approval and commercialization of these products in the international market are key issues that would determine the success of firms in the future.

In this context, Dr. Reddy's Laboratories has been making significant strides in the biologics space, with the firm's Bachupally site and biosimilar products becoming a point of interest. The progress that Dr. Reddy's Laboratories is making in this area can well turn out to be a key issue for investors.

With a market capitalisation of Rs. 1,01,918 cr, the shares of Dr Reddys Laboratories Ltd...